Organon & Co (OGN) Stock

The latest trading day saw Organon (OGN) settling at $15.97, representing a +0.82% change from its previous close.

Organon (OGN) closed at $16.26 in the latest trading session, marking a +1.82% move from the prior day.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025.

Organon (OGN) closed the most recent trading day at $15.88, moving +0.89% from the previous trading session.

Organon has faced significant price volatility and underperformance since its spin-off from Merck, with shares down ~50% since 2021. Key products like Nexplanon and VTAMA are crucial for future growth, but uncertainties and competition pose significant risks to revenue projections. Organon's high debt and interest payments are significant concerns, despite low P/S and P/E ratios suggesting undervaluation, and a strong dividend yield.

Organon & Co. (NYSE:OGN ) JPMorgan Annual Healthcare Conference Call January 13, 2025 6:45 PM ET Company Participants Kevin Ali - Chief Executive Officer Matthew Walsh - Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody. I'm Chris Schott from JPMorgan and it's my pleasure to be hosting this fireside chat with the Organon management team.

Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.

Organon (OGN) closed at $15.06 in the latest trading session, marking a +0.74% move from the prior day.

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.